poisar

Stocks · News reference

Citigroup Maintains Buy on Nebius Group, Lowers Price Target to $265

BenzingaBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. The Motley FoolDaniel Sparks

    Nebius Stock: The Bull Case, the Bear Case, and My Call Before Nov. 12

    Nebius Group stock has fallen 47% from its June peak to around $152. The bull case rests on management's target of $7-9 billion annualized run-rate revenue by year-end 2026 (up from $3 billion in June), with the company demonstrating strong growth momentum. However, the bear case highlights massive capital expenditure needs ($20-25 billion in 2026) requiring significant external funding, customer concentration risk (3 customers = 59% of revenue), and reliance on share dilution and debt. The analyst recommends waiting for Q3 results on Nov. 12 to assess if the company remains on track for its targets before making an investment decision.

  2. The Motley FoolTrevor Jennewine

    3 Nasdaq-100 Stocks That Can Double, According to Wall Street

    Wall Street analysts identify three Nasdaq-100 stocks with potential to double based on median target prices: CoreWeave (140% upside) as a leading AI cloud provider with strong revenue growth but profitability concerns due to high debt; Nebius Group (100% upside) as an emerging AI cloud competitor with faster revenue growth but expensive valuation; and Alnylam Pharmaceuticals (100% upside) as an RNA interference therapy leader with an attractive valuation and promising pipeline.